UK health authorities review the safety of a heart medication that is also used off-label to ease anxiety symptoms, following reports of overdoses and deaths. The outlets cite a year of concerning outcomes, including 300 overdoses and 12 deaths, and note that prescriptions for the drug have increased.
The reports frame the issue as a safety concern tied to wider prescribing practices. They describe the drug as being prescribed beyond its original heart-related indication to manage anxiety, and they say health chiefs are assessing risks associated with its use. The coverage emphasizes the scale of adverse events and the growth in prescriptions, while not detailing specific regulatory findings or changes at the time of publication. The overall focus is on potential harm linked to overdose and the need for reassessment of whether the off-label use remains appropriate under current conditions.
